Abstract
In order to explore structure-activity relationship (SAR) associated with xanthone framework, a series of prenylated xanthone derivatives 2-9 was synthesized from the key building block 1,3,6,8-tetrahydroxyxanthone 1 and evaluated for their in vitro growth inhibitory activities against HeLa and MDA-MB-231 human cancer cell lines. The in vitro evidence indicated that the inhibitory activity was significantly influenced by the position and number of linked group on the xanthone skeleton, and the presence of chroman-4-one moiety in the xanthone scaffold was found to be critically important for strong cytotoxic activity. The novel 2H-xanthene-3,9-dione analogues 3 and 4 were reported to elicit potent activities comparable to those of standard drugs doxorubicin and cisplatin. This preliminary investigation has highlighted the therapeutic potential of 2H-xanthene-3,9-dione derivatives to be exploitable as lead compound for the development of potent HeLa and MDA-MB-231 cancer cell inhibitors.
Keywords: Cytotoxicity, 2H-xanthene-3,9-dione scaffold, 2H-xanthene-3,6,9(7H)-trione scaffold, Inhibitory activity, Synthesis, Xanthone derivatives, SAR, Xanthone, HeLa, MDA-MB-231, Cancer, prenylated, anti-inflammatory, 1,3-dihydroxyxanthone, phloroglucinol, acylphloroglucinols
Letters in Drug Design & Discovery
Title: Synthesis and SAR Study of Prenylated Xanthone Analogues as HeLa and MDA-MB-231 Cancer Cell Inhibitors
Volume: 8 Issue: 6
Author(s): Chan Kiang Lim, Lai-Yeng Tho, Cheng Hoe Lim, Yang Mooi Lim, Syed Adnan Ali Shah and Jean-Frederic Faizal Weber
Affiliation:
Keywords: Cytotoxicity, 2H-xanthene-3,9-dione scaffold, 2H-xanthene-3,6,9(7H)-trione scaffold, Inhibitory activity, Synthesis, Xanthone derivatives, SAR, Xanthone, HeLa, MDA-MB-231, Cancer, prenylated, anti-inflammatory, 1,3-dihydroxyxanthone, phloroglucinol, acylphloroglucinols
Abstract: In order to explore structure-activity relationship (SAR) associated with xanthone framework, a series of prenylated xanthone derivatives 2-9 was synthesized from the key building block 1,3,6,8-tetrahydroxyxanthone 1 and evaluated for their in vitro growth inhibitory activities against HeLa and MDA-MB-231 human cancer cell lines. The in vitro evidence indicated that the inhibitory activity was significantly influenced by the position and number of linked group on the xanthone skeleton, and the presence of chroman-4-one moiety in the xanthone scaffold was found to be critically important for strong cytotoxic activity. The novel 2H-xanthene-3,9-dione analogues 3 and 4 were reported to elicit potent activities comparable to those of standard drugs doxorubicin and cisplatin. This preliminary investigation has highlighted the therapeutic potential of 2H-xanthene-3,9-dione derivatives to be exploitable as lead compound for the development of potent HeLa and MDA-MB-231 cancer cell inhibitors.
Export Options
About this article
Cite this article as:
Kiang Lim Chan, Tho Lai-Yeng, Hoe Lim Cheng, Mooi Lim Yang, Adnan Ali Shah Syed and Faizal Weber Jean-Frederic, Synthesis and SAR Study of Prenylated Xanthone Analogues as HeLa and MDA-MB-231 Cancer Cell Inhibitors, Letters in Drug Design & Discovery 2011; 8 (6) . https://dx.doi.org/10.2174/157018011795906820
DOI https://dx.doi.org/10.2174/157018011795906820 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synergistic Effect of the Combination of Novel Suberoylanilide Hydroxamic Acid Derivatives with Cisplatin on Anti-proliferation of Human Cancer Cells
Medicinal Chemistry Biomedical Applications of Gold Nanoparticles
Current Topics in Medicinal Chemistry Potential Utilization of Bystander / Abscopal-Mediated Signal Transduction Events in the Treatment of Solid Tumors
Current Signal Transduction Therapy Genomic Instability in Cancer: Molecular Mechanisms and Therapeutic Potentials
Current Pharmaceutical Design The Impact of the Activated Stroma on Pancreatic Ductal Adenocarcinoma Biology and Therapy Resistance
Current Molecular Medicine Histone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Natural Products As Antimitotic Agents
Current Topics in Medicinal Chemistry A Rapid One-step Synthesis of Isoflavanone Compounds Under Microwave Irradiation
Current Microwave Chemistry The Paradox of Oestradiol-Induced Breast Cancer Cell Growth and Apoptosis
Current Signal Transduction Therapy Effects of Bioactive Peptide on Inflammatory Bowel Disease, Focus on Signal Transduction and Intestinal Microbiota
Current Pharmaceutical Design The Role of Integrin-Mediated Cell Adhesion in Atherosclerosis: Pathophysiology and Clinical Opportunities
Current Pharmaceutical Design Nanotechnology on Duty in Medical Applications
Current Pharmaceutical Biotechnology Prerequisite of a Holistic Blend of Traditional and Modern Approaches of Cancer Management
Current Cancer Therapy Reviews Matrix Metalloproteinase Inhibition in Atherosclerosis and Stroke
Current Molecular Medicine Insights into the Design of p97-targeting Small Molecules from Structural Studies on p97 Functional Mechanism
Current Medicinal Chemistry Current Prodrug Strategies for the Delivery of Nucleotides into Cells
Drug Design Reviews - Online (Discontinued) Crucial Protein Based Drug Targets and Potential Inhibitors for Osteoporosis: New Hope and Possibilities
Current Drug Targets Perspectives on Medicinal Properties of Benzoquinone Compounds
Mini-Reviews in Medicinal Chemistry The Role of Nucleoside Transport in the Antineoplastic Activity of Purine Nucleoside Chemotherapeutic Agents
Current Cancer Therapy Reviews Targeting the Kinetochore in Cancer Therapy: The Ndc80/Hec1 Complex
Current Drug Therapy